A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

May 31, 2018

Astellas Submits Application for Approval of Peficitinib for Rheumatoid Arthritis (Including Prevention of Structural Joint Damage) in Patients Who Have an Inadequate Response to Conventional Therapies in Japan

TOKYO, May 31, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has submitted an application for marketing approval of peficitinib...

Read more about Astellas Submits Application for Approval of Peficitinib for Rheumatoid Arthritis (Including Prevention of Structural Joint Damage) in Patients Who Have an Inadequate Response to Conventional Therapies in Japan
May 31, 2018

Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia

TOKYO and San Francisco, May 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”

Read more about Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia
May 31, 2018

Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving -Cancer Care in Underserved Regions of the World-

TOKYO – May 31, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the launch of the third annual Astellas Oncology C3 Prize...

Read more about Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving -Cancer Care in Underserved Regions of the World-
May 29, 2018

U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

TOKYO – May 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted,...

Read more about U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 24, 2018

Addition of Mirabegron to Tamsulosin Demonstrates Superior Efficacy Compared to Placebo in Men with Overactive Bladder Symptoms

TOKYO – May 24, 2018 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the post-marketing MATCH study exploring use of mirabegron versus...

Read more about Addition of Mirabegron to Tamsulosin Demonstrates Superior Efficacy Compared to Placebo in Men with Overactive Bladder Symptoms

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts